NanoString revs up for U.S. launch of breast cancer prognostic Dx

NanoString Technologies ($NSTG) won a coveted 510(k) clearance for its new in vitro breast cancer diagnostic. And as it gears up for a U.S. launch, the Seattle company sees the Prosigna test as a potential game-changer, because the test kits and related hardware can be bought and run by any high-complexity CLIA lab. Typically, these types of diagnostic tests are available only at special centralized labs, Nanostring CEO Brad Gray told FierceDiagnostics. The test is based on the PAM50 gene signature and is designed to profile cells found in breast cancer tissue to assess a patient's risk of future recurrence of the disease. Story

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.